These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38471416)

  • 1. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
    Kim DW; Chul Cho B; Pachipala K; Kim SW; Wang CL; Chang GC; Ahn MJ; Alvarez R; Chiu CH; Trigo J; Estival A; Karam SD; O'Brien C; Gowda H; Jiang H; Bauman JE
    Lung Cancer; 2024 Apr; 190():107530. PubMed ID: 38471416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
    Nakamichi S; Kubota K; Misumi T; Kondo T; Murakami S; Shiraishi Y; Imai H; Harada D; Isobe K; Itani H; Takata S; Wakui H; Misumi Y; Ikeda S; Asao T; Furuya N; Hosokawa S; Kobayashi Y; Takiguchi Y; Okamoto H
    Clin Cancer Res; 2024 Mar; 30(6):1104-1110. PubMed ID: 38165684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
    Vokes EE; Mornex F; Sezer A; Cheng Y; Fang J; Baz DV; Cil T; Adjei AA; Ahn MJ; Barlesi F; Felip E; Garon EB; Audhuy F; Ito R; Sato M; Eggleton SP; Martin CM; Reck M; Robinson CG; Paz-Ares L
    J Thorac Oncol; 2024 Feb; 19(2):285-296. PubMed ID: 37797733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
    Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
    Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
    Garassino MC; Mazieres J; Reck M; Chouaid C; Bischoff H; Reinmuth N; Cove-Smith L; Mansy T; Cortinovis D; Migliorino MR; Delmonte A; Sánchez JG; Chara Velarde LE; Bernabe R; Paz-Ares L; Perez ID; Trunova N; Foroutanpour K; Faivre-Finn C
    J Thorac Oncol; 2022 Dec; 17(12):1415-1427. PubMed ID: 35961520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
    Kaira K; Mouri A; Kato S; Yoshimura K; Kagamu H; Kobayashi K
    BMC Cancer; 2020 Oct; 20(1):961. PubMed ID: 33023530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
    Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
    Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
    Tachihara M; Tsujino K; Ishihara T; Hayashi H; Sato Y; Kurata T; Sugawara S; Shiraishi Y; Teraoka S; Azuma K; Daga H; Yamaguchi M; Kodaira T; Satouchi M; Shimokawa M; Yamamoto N; Nakagawa K;
    JAMA Oncol; 2023 Nov; 9(11):1505-1513. PubMed ID: 37676681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
    Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Tamiya A; Iwasawa S; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Hirano K; Kokubo M; Yamamoto N
    Invest New Drugs; 2021 Jun; 39(3):853-859. PubMed ID: 33405089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
    Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Taniguchi Y; Hino A; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Matsumoto H; Kokubo M; Yamamoto N
    Lung Cancer; 2022 Sep; 171():3-8. PubMed ID: 35863254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
    Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
    Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
    Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
    J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
    Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
    Yamada T; Goto Y; Tanaka H; Kimura H; Minato K; Gyotoku H; Honda T; Watanabe S; Morimoto K; Kiyomi F; Uchino J; Takayama K
    Eur J Cancer; 2023 Dec; 195():113373. PubMed ID: 37890349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
    Durm GA; Jabbour SK; Althouse SK; Liu Z; Sadiq AA; Zon RT; Jalal SI; Kloecker GH; Williamson MJ; Reckamp KL; Langdon RM; Kio EA; Gentzler RD; Adesunloye BA; Harb WA; Walling RV; Titzer ML; Hanna NH
    Cancer; 2020 Oct; 126(19):4353-4361. PubMed ID: 32697352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
    Tanaka H; Hasegawa Y; Makiguchi T; Okumura F; Tabe C; Shiratori T; Ishioka Y; Itoga M; Taima K; Yokouchi J; Hatayama Y; Aoki M; Tasaka S
    Clin Lung Cancer; 2021 Jan; 22(1):42-48. PubMed ID: 33158764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program.
    Avrillon V; Daniel C; Boisselier P; Le Péchoux C; Chouaid C
    Lung; 2022 Feb; 200(1):95-105. PubMed ID: 35141799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
    Herbst RS; Majem M; Barlesi F; Carcereny E; Chu Q; Monnet I; Sanchez-Hernandez A; Dakhil S; Camidge DR; Winzer L; Soo-Hoo Y; Cooper ZA; Kumar R; Bothos J; Aggarwal C; Martinez-Marti A
    J Clin Oncol; 2022 Oct; 40(29):3383-3393. PubMed ID: 35452273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
    De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
    Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.
    Lin Q; Liu YE; Ren XC; Wang N; Chen XJ; Wang DY; Zong J; Peng Y; Guo ZJ; Hu J
    Radiat Oncol; 2013 Aug; 8(1):201. PubMed ID: 23957889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.